A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 441-446

  Garcia Feijoo, Julian ^a   Sampaolesi, Juan Roberto ^b  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b Ciudad de Buenos Aires   (Argentina)

Author keywords

Correlation; Number of medications; OSDI; Time since diagnosis

Indexed keywords

AGENTS ACTING ON THE EYE; BENZALKONIUM CHLORIDE; INTRAOCULAR PRESSURE LOWERING DRUG; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLOSED ANGLE GLAUCOMA; DETERIORATION; DISEASE DURATION; DISEASE SEVERITY; EYE DISEASE; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OCULAR SURFACE DISEASE; OCULAR SURFACE DISEASE INDEX; OPEN ANGLE GLAUCOMA; PREVALENCE; PSEUDOEXFOLIATION; SCORING SYSTEM; SYMPTOM;

EID: 84930472368     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S29158     Document Type: Article

References (23)

1. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):75-92.
2. Stewart WC, Stewart JA, Nelson LA. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res. 2011;36(5):391-398.
3. Lemp MA. Advances in understanding and managing dry eye disease. Am J Ophthalmol. 2008;146(3):350-356.
4. Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol. 2009;3:405-412.
5. Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;135(1):1-9.
6. Friedman NJ. Impact of dry eye disease and treatment on quality of life. Curr Opin Ophthalmol. 2010;21(4):310-316.
7. Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care. 2008;14(3 Suppl):S102-S106.
8. Schein OD, Hochberg MC, Muñoz B, et al. Dry eye and dry mouth in the elderly: a population-based assessment. Arch Intern Med. 1999;159(12):1359-1363.
9. Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312-334.
10. Lemp MA. Management of dry eye disease. Am J Manag Care. 2008;14(3 Suppl):S88-S101.
11. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350-355.
12. Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29(6):618-621.
13. Rossi GC, Tinelli C, Pasinetti GM, Milano G, Bianchi PE. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009;19(4):572-579.
14. Rossi GCM. How to diagnose the ocular surface disease in treated glaucoma patients. Eur Ophthalmic Rev. 2011;5(1):38-42.
15. Schiffman RM, Christianson MD, Jacobsen G. Reliability and validity of the ocular surface disease index. Arch Ophthalmol. 2000;118(5):615-621.
16. Erb C, Gast U, Schremmer D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol. 2008;246(11):1593-1601.
17. Furrer P, Mayer JM, Gurny R. Ocular tolerance of preservatives and alternatives. Eur J Pharm Biopharm. 2002;53(3):263-280.
18. Kaur IP, Lal S, Rana C, Kakkar S, Singh H. Ocular preservatives: associated risks and newer options. Cutan Ocul Toxicol. 2009;28(3): 93-103.
19. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18(5):205-215.
20. Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol. 2007;18(2):134-139.
21. Servat JJ, Bernardino CR. Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue. Drugs Aging. 2011;28(4):267-282.
22. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112(5):863-868.
23. Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea. 2004;23(8):762-770.